Traders sold shares of Gilead Sciences Inc. (NASDAQ:GILD) on strength during trading hours on Monday. $198.58 million flowed into the stock on the tick-up and $257.44 million flowed out of the stock on the tick-down, for a money net flow of $58.86 million out of the stock. Of all stocks tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.99 for the day and closed at $80.46

A number of equities research analysts have commented on the company. Vetr lowered Gilead Sciences from a “buy” rating to a “hold” rating and set a $105.42 price target on the stock. in a research report on Thursday, April 21st. Credit Suisse Group AG reiterated an “outperform” rating and issued a $120.00 price target (up previously from $116.00) on shares of Gilead Sciences in a research report on Thursday, April 28th. Cowen and Company reiterated a “buy” rating on shares of Gilead Sciences in a research report on Sunday, April 17th. Robert W. Baird reiterated an “outperform” rating and issued a $135.00 price target on shares of Gilead Sciences in a research report on Tuesday, April 12th. Finally, Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, April 29th. Eleven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $107.37.

The company has a 50-day moving average price of $83.91 and a 200-day moving average price of $88.28. The company has a market capitalization of $107.09 billion and a PE ratio of 7.06.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, topping analysts’ consensus estimates of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to analysts’ expectations of $7.80 billion. During the same quarter in the previous year, the firm earned $3.15 earnings per share. Gilead Sciences’s revenue was down 5.7% on a year-over-year basis. On average, equities research analysts anticipate that Gilead Sciences Inc. will post $11.77 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Friday, September 16th will be issued a $0.47 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.34%.

In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $83.12, for a total transaction of $166,240.00. Following the completion of the sale, the executive vice president now directly owns 63,122 shares in the company, valued at approximately $5,246,700.64. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO John F. Milligan sold 112,000 shares of the business’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $86.94, for a total transaction of $9,737,280.00. Following the sale, the chief executive officer now owns 1,170,963 shares of the company’s stock, valued at $101,803,523.22. The disclosure for this sale can be found here.

A number of large investors recently made changes to their positions in GILD. Capital Counsel LLC NY raised its stake in shares of Gilead Sciences by 0.3% in the fourth quarter. Capital Counsel LLC NY now owns 86,935 shares of the biopharmaceutical company’s stock worth $8,797,000 after buying an additional 280 shares in the last quarter. Oarsman Capital Inc. raised its stake in shares of Gilead Sciences by 1.0% in the fourth quarter. Oarsman Capital Inc. now owns 21,341 shares of the biopharmaceutical company’s stock worth $2,159,000 after buying an additional 205 shares in the last quarter. Airain ltd raised its stake in shares of Gilead Sciences by 40.5% in the fourth quarter. Airain ltd now owns 155,921 shares of the biopharmaceutical company’s stock worth $15,778,000 after buying an additional 44,970 shares in the last quarter. KBC Group NV raised its stake in shares of Gilead Sciences by 4.3% in the fourth quarter. KBC Group NV now owns 513,329 shares of the biopharmaceutical company’s stock worth $51,944,000 after buying an additional 21,151 shares in the last quarter. Finally, TrimTabs Asset Management LLC raised its stake in shares of Gilead Sciences by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 19,871 shares of the biopharmaceutical company’s stock worth $2,011,000 after buying an additional 369 shares in the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.